摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-steganol | 41451-71-2

中文名称
——
中文别名
——
英文名称
(+/-)-steganol
英文别名
steganol;(9R,13R,14R)-14-hydroxy-3,4,5-trimethoxy-11,18,20-trioxapentacyclo[13.7.0.02,7.09,13.017,21]docosa-1(22),2,4,6,15,17(21)-hexaen-10-one
(+/-)-steganol化学式
CAS
41451-71-2;41451-72-3;58800-44-5;58800-46-7;61176-78-1;107439-62-3;107439-63-4;107439-64-5
化学式
C22H22O8
mdl
——
分子量
414.412
InChiKey
VLOMFQZOMYZLFI-TYILLQQXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    30
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    92.7
  • 氢给体数:
    1
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Asymmetric total synthesis of natural (-)-and unnatural (+)-steganacin
    作者:Kiyoshi Tomioka、Tsuneo Ishiguro、Yōichi Iitaka、Kenji Koga
    DOI:10.1016/s0040-4020(01)82416-9
    日期:1984.1
    A virtually complete asymmetric control in the synthesis of 2,3-disubstituted butan-4-olide (10) was demonstrated by employing the butenolide (12) as the chiral acceptor for the conjugate 1,4-addition. Highly efficient asymmetric total synthesis of natural (-)- and unnatural (+)-steganacin was accomplished. The absolute stereostructure of natural antitumor steganain was determined to be 1.
    通过使用丁烯内酯(12)作为共轭1,4-加成的手性受体,证明了合成2,3-二取代的丁-4-醇(10)时几乎完全不对称。完成了天然(-)-和非天然(+)-甜菊糖的高效不对称全合成。天然抗肿瘤甜菜碱的绝对立体结构被确定为1。
  • Syntheses totales et etudes de lignanes biologiquement actifs. application de l'α-hydroxyalkylation de β-benzyl γ-butyrolactones a la creation des squelettes phenyl tetraline et bisbenzocyclooctadiene—4
    作者:Robert Dhal、Eric Brown、Jean-Pierre Robin
    DOI:10.1016/s0040-4020(01)82447-9
    日期:1983.1
    The biphenyl 16 (obtained from α-bromopiperonal and the aromatic iodide 14 by a modified Ullmann reaction) was cyclized by intramolecular hydroxyalkylation to the isomeric alcohols 17a and 17b. These were oxidized using Jones' reagent, to afford the enol 18a, together with the tautomeric β-ketolactone Decarboxylation of this mixture using barium hydroxide, followed by Jones' oxidation gave the isomeric
    通过分子内羟烷基化将联苯16(通过改良的Ullmann反应从α-溴代戊二醛和芳香族碘化物14中获得)环化为异构醇17a和17b。使用Jones′试剂将它们氧化,得到烯醇18a,以及使用氢氧化钡将该混合物的互变异构体β-酮内酯脱羧,然后进行Jones′氧化,得到异构体γ-酮酸11a和11b。使用Raphael方法将这些化合物转化为(±)-steganone 1,从3,4,5-三甲氧基苯甲醛开始的总收率约为10%,从联苯16开始的总收率为20.7%。。
  • Stereoselective reactions. VIII. Stereochemical requirement for the benzylic oxidation of lignan lactone. A highly selective synthesis of the antitumor lignan lactone steganacin by the oxidation of stegane.
    作者:TSUNEO ISHIGURO、HIDEMICHI MIZUGUCHI、KIYOSHI TOMIOKA、KENJI KOGA
    DOI:10.1248/cpb.33.609
    日期:——
    A highly efficient synthesis of the antitumor steganin lignan steganacin (1) was accomplished. Bromination of stegane (7) with N-bromosuccinimide followed by treatment with aqueous tetrahydrofuran afforded steganol (3) in 85% yield. Acetylation of 3 gave 1 in 72% yield. Stegane (7) was also oxidized with 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone in AcOH to give 1 directly in 10% yield. Stereochemical requirements for the benzylic oxidation of dibenzocyclooctadiene lignan lactones are discussed.
    我们完成了抗肿瘤甜菜苷木质素甜菜苷(1)的高效合成。用 N-溴代丁二酰亚胺溴化 stegane (7),然后用四氢呋喃水溶液处理,可得到 steganol (3),收率为 85%。对 3 进行乙酰化后得到 1,收率为 72%。Stegane (7) 也在 AcOH 中与 2,3-二氯-5,6-二氰基-1,4-苯醌发生氧化反应,直接得到 1,收率为 10%。讨论了二苯并环辛二烯木质素内酯苄基氧化的立体化学要求。
  • Stereoselective reactions. XII Synthesis of antitumor-active steganacin analogs, picrosteganol and epipicrosteganol, by selective isomerization.
    作者:KIYOSHI TOMIOKA、TSUNEO ISHIGURO、YOICHI IITAKA、KENJI KOGA
    DOI:10.1248/cpb.34.1501
    日期:——
    New steganacin analogs with definite absolute configurations, (-)-picro- and (-)-epipicrosteganol, were synthesized by isomerization of (-)-steganol and (-)-episteganol, respectively, at the α-position to the lactone carbonyl. The structure of (-)-epipicrosteganol was confirmed by X-ray crystallographic analysis. Selective epimerization at the C-4 benzylic position was observed upon acidic treatment of (-)-steganacin, giving (-)-episteganacin.
    通过分别在内酯羰基的 α 位上异构化 (-)-十八烷醇和 (-)-表十八烷醇,合成了具有明确绝对构型的新型隐甲星烷酸类似物 (-)-苦味- 和 (-)-表隐甲烷醇。通过X射线晶体学分析证实了(-)-表吡甾烷醇的结构。在对(-)-steganacin进行酸性处理后,观察到C-4苄基位置的选择性差向异构化,得到(-)-episteganacin。
  • Stereoselective reactions. XVII. Absolute structure-cytotoxic activity relationships of steganacin congeners and analogs
    作者:Kiyoshi Tomioka、Tsuneo Ishiguro、Hidemichi Mizuguchi、Nobuyasu Komeshima、Kenji Koga、Shigeru Tsukagoshi、Takashi Tsuruo、Tazuko Tashiro、Seiichi Tanida、Toyokazu Kishi
    DOI:10.1021/jm00105a009
    日期:1991.1
    The cytotoxic activities of optically pure and racemic steganacin congeners and analogues against KB cells in culture and the inhibitor activity of cilia regeneration in Tetrahymena were studied with regard to absolute and retative configurations. The stereochemical requirements of dibenzocyclooctadiene lignan lactones for activity were clarified.
查看更多

同类化合物

鬼臼脂毒酮 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 苦鬼臼毒素 脱氧鬼臼毒素 磷酸依托泊甙 盾叶鬼臼素 澳白木脂素2 澳白木脂素1 替尼泊苷 托尼依托泊苷 去氧鬼臼毒素 克立米星C 他氟泊苷 丙氨酸,N-(羧基甲基)-(9CI) alpha-盾叶鬼臼素 alpha-依托泊苷 [(5R,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-8-氧代-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-5-基]丁酸酯 TOP-53二盐酸盐 NK-611盐酸盐 5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-(5R,5aR,8aR,9S)-呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5aH)-酮 4’-去甲鬼臼毒素 4’-去甲基表鬼臼毒素-Β-D-葡萄糖甙 4-{[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]氨基甲酰}苯基乙酸酯 4,6-O-苄叉-Β-D-葡萄糖甙鬼臼毒素 4'-去甲基表鬼臼毒素 4'-O-脱甲基-4-((4'-(1'-苯甲基哌啶基))氨基)-4-脱氧鬼臼毒 4 ’-去甲去氧鬼臼毒素 3-羟基-4H-吡喃-4-酮 3-氨基-N-[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]苯酰胺 2’-O-没食子酰基金丝桃甙 2(3H)-硫代酰苯,3-乙基二氢-3-(1-甲基乙基)-(9CI) 2'-氯依托泊苷 1-羟基-17-氧杂五环[6.6.5.0~2,7~.0~9,14~.0~15,19~]十九碳-2,4,6,9,11,13-六烯-16,18-二酮(non-preferredname) (8aR,9S)-9-[[(2R)-7,8-二羟基-2-(2-噻吩基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5S,5aS,8aR,9R)-5-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基-苯基)-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-8-酮 (5S,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-5-(4-羟基苯基)硫烷基-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二噁唑-8-酮 (5R,5aR,8aS,9S)-9-[(4-氨基苯基)氨基]-5-(4-羟基-3,5-二甲氧苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-6(5aH)-酮盐酸(1:1) (5R,5aR,8aR,9R)-9-羟基-10-甲氧基-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(4-甲氧基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(2-羟基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-8-羰基-9-(3,4,5-三甲氧苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基乙酸酯 (5R,5aR,8aR,9R)-5-(4-乙氧基-3,5-二甲氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-5-(3,5-二甲氧基-4-丙氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R)-5,8,8ab,9-四氢-5b-(3,4,5-三甲氧基苯基)呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5abH),9-二酮 (5-氯吡啶-3-基)丙酸甲酯 (3aS,4S,9R,9aR)-4-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基苯基)-6,7-二甲氧基-3a,4,9,9a-四氢-3H-萘并[3,2-c]呋喃-1-酮 (3aR,4S,9R,9aR)-4,6,7-三羟基-9-(4-羟基-3,5-二甲氧苯基)-3a,4,9,9a-四氢萘并[2,3-c]呋喃-1(3H)-酮 (1R,3aS,4R,6aR)-4-(1,3-苯并二氧戊环-4-基)-1-(1,3-苯并二氧戊环-5-基)-3,3a,4,6a-四氢-1H-呋喃并[3,4-c]呋喃-6-酮